Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cobicistat

FDA-approved product (tablet, oral), marketed as Cobicistat, Tybost.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Cobicistat
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other therapeutic products
FDA pharmacologic class
Cytochrome P450 3A Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cobicistat in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cobicistat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study

    NCT07462559 · start 2026-03-04

    Registered record
    Registry ID
    NCT07462559
    Conditions
    Drug Drug Interaction
    Interventions
    Ketamine 10 mg/ml oral solution, UK special; Cobisistat Tybost 150 mg; Cannabidiol Epidyolex 100 mg/ml
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-03-04
    Completion
    2026-12-31
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Drug Interaction
    InterventionKetamine 10 mg/ml oral solution, UK special; Cobisistat Tybost 150 mg; Cannabidiol Epidyolex 100 mg/ml
    PhasePhase 1
    Registry statusNot yet recruiting

  • A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

    NCT06337032 · start 2024-08-27

    Registered record
    Registry ID
    NCT06337032
    Conditions
    HIV-1-infection
    Interventions
    F/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS); F/TAF (Low Dose TOS); F/TAF (Lowest Dose TOS); E/C/F/TAF; E/C/F/TAF (Low Dose); Cobicistat (High Dose); Cobicistat (Low Dose); Cobicistat (TOS); B/F/TAF (High Dose); B/F/TAF (Low Dose); B/F/TAF (High Dose TOS); B/F/TAF (Low Dose TOS); B/F/TAF (Lowest Dose TOS); 3rd ARV Agent; Nucleos(t)ide reverse transcriptase inhibitors (NRTI); ATV; DRV; Lopinavir Boosted with ritonavir (LPV/r)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-27
    Completion
    2034-03
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionF/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS) +17 more
    PhasePhase 4
    Registry statusRecruiting

  • A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

    NCT05729568 · start 2023-05-15

    Registered record
    Registry ID
    NCT05729568
    Conditions
    HIV-1 Infection
    Interventions
    Teropavimab; Zinlirvimab; Lenacapavir Tablet; Lenacapavir Injection; Antiretroviral Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-05-15
    Completion
    2030-12
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionTeropavimab; Zinlirvimab; Lenacapavir Tablet; Lenacapavir Injection +1 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Electrophysiological Effects of Potential QT Prolonging Drugs

    NCT05716854 · start 2023-03-21

    Registered record
    Registry ID
    NCT05716854
    Conditions
    Drug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics
    Interventions
    Clarithromycin; Pimozide; Placebo (Part 1); Moxifloxacin; Cobicistat; Moxifloxacin and Cobicistat; Placebo (Part 2)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-03-21
    Completion
    2023-06-13
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-induced QT Prolongation; Pharmacokinetics; Pharmacodynamics
    InterventionClarithromycin; Pimozide; Placebo (Part 1); Moxifloxacin +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

    NCT05236738 · start 2022-05-13

    Registered record
    Registry ID
    NCT05236738
    Conditions
    Healthy Participants
    Interventions
    Atazanavir; Cobicistat; Atazanavir/Cobicistat Mini-tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-05-13
    Completion
    2022-07-26
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAtazanavir; Cobicistat; Atazanavir/Cobicistat Mini-tablet
    PhasePhase 1
    Registry statusCompleted

  • Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

    NCT04388904 · start 2021-09-01

    Registered record
    Registry ID
    NCT04388904
    Conditions
    HIV-1-infection
    Interventions
    Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-09-01
    Completion
    2024-04-05
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionDarunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

    NCT04518228 · start 2021-09-01

    Registered record
    Registry ID
    NCT04518228
    Conditions
    HIV; Tuberculosis
    Interventions
    Bictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG); Atazanavir/ritonavir (ATV/r); Darunavir/ritonavir (DRV/r); Lopinavir/ritonavir (LPV/r); Cobicistat; Ritonavir; First-Line TB Treatment; Second-Line TB Treatment; Doravirine (DOR)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2021-09-01
    Completion
    2025-07-10
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Tuberculosis
    InterventionBictegravir (BIC); Tenofovir alafenamide (TAF); Long-acting injectable formulation of cabotegravir (CAB LA); Dolutegravir (DTG) +8 more
    PhaseNot recorded
    Registry statusTerminated

  • Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria

    NCT04709692 · start 2021-04-14

    Registered record
    Registry ID
    NCT04709692
    Conditions
    Malaria, Falciparum; Malaria, Vivax
    Interventions
    (+)-SJ000557733 (SJ733)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-04-14
    Completion
    2022-04-15
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum; Malaria, Vivax
    Intervention(+)-SJ000557733 (SJ733)
    PhasePhase 2
    Registry statusCompleted

  • A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents

    NCT04661397 · start 2021-01-05

    Registered record
    Registry ID
    NCT04661397
    Conditions
    Healthy
    Interventions
    Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC; Darunavir; Emtricitabine/Tenofovir Alafenamide; Cobicistat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-01-05
    Completion
    2021-07-02
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDarunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC; Darunavir; Emtricitabine/Tenofovir Alafenamide; Cobicistat
    PhasePhase 1
    Registry statusCompleted

  • Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

    NCT04653194 · start 2020-09-30

    Registered record
    Registry ID
    NCT04653194
    Conditions
    Human Immunodeficiency Virus
    Interventions
    Biktarvy; Symtuza
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-09-30
    Completion
    2023-07-31
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus
    InterventionBiktarvy; Symtuza
    PhasePhase 3
    Registry statusCompleted

  • Contribution of Dolutegravir to Obesity and Cardiovascular Disease

    NCT04340388 · start 2020-09-17

    Registered record
    Registry ID
    NCT04340388
    Conditions
    HIV-1-infection; Antiviral Drug Adverse Reaction; Vascular Diseases; Cardiovascular Abnormalities; Abnormality of Adipose Tissue; Body Weight Changes; Body Fat Disorder; HIV-Associated Lipodystrophy Syndrome
    Interventions
    Dolutegravir 50 MG; Antiretroviral/Anti HIV
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-09-17
    Completion
    2023-02-25
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection; Antiviral Drug Adverse Reaction; Vascular Diseases; Cardiovascular Abnormalities +4 more
    InterventionDolutegravir 50 MG; Antiretroviral/Anti HIV
    PhasePhase 4
    Registry statusCompleted

  • Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19

    NCT04386447 · start 2020-09-01

    Registered record
    Registry ID
    NCT04386447
    Conditions
    Covid-19; Corona Virus Infection; SARS-CoV 2
    Interventions
    Oxytocin; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2020-09-01
    Completion
    2020-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid-19; Corona Virus Infection; SARS-CoV 2
    InterventionOxytocin; Standard of Care
    PhasePhase 2
    Registry statusWithdrawn

  • Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients

    NCT04475120 · start 2020-04-15

    Registered record
    Registry ID
    NCT04475120
    Conditions
    Covid19
    Interventions
    liposomal lactoferrin; SOC therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2020-04-15
    Completion
    2020-07-02
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCovid19
    Interventionliposomal lactoferrin; SOC therapy
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar

    NCT04425382 · start 2020-03-01

    Registered record
    Registry ID
    NCT04425382
    Conditions
    Coronavirus; COVID; Pneumonia
    Interventions
    Darunavir/Cobicistat; Lopinavir/Ritonavir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-03-01
    Completion
    2020-09-30
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronavirus; COVID; Pneumonia
    InterventionDarunavir/Cobicistat; Lopinavir/Ritonavir
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

    NCT04263350 · start 2020-02-26

    Registered record
    Registry ID
    NCT04263350
    Conditions
    Healthy Participants
    Interventions
    Atazanavir/Cobicistat; Reyataz Atazanavir; Cobicistat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-26
    Completion
    2020-11-17
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAtazanavir/Cobicistat; Reyataz Atazanavir; Cobicistat
    PhasePhase 1
    Registry statusCompleted